## Contents

### Index

<table>
<thead>
<tr>
<th>List of Tables</th>
<th>i</th>
</tr>
</thead>
<tbody>
<tr>
<td>List of Figures</td>
<td>iii</td>
</tr>
<tr>
<td>List of Abbreviations</td>
<td>vi</td>
</tr>
</tbody>
</table>

### Chapter 1

**GENERAL INTRODUCTION** 1-26

1.1. Definition of breast cancer 2

1.2. Anatomy of breast
   - 1.2.1. Adipose tissue, lobules and milk duct 2
   - 1.2.2. The lymph system 3

1.3. Basic mechanism for the growth of breast cancer 4
   - 1.3.1. Damaged cells replicate, creating more damaged cells and tumor growth 4
   - 1.3.2. Our body's hormones and chemicals can accelerate the growth of some tumors 4
   - 1.3.3. Lymph and blood vessels can carry the cancer to others areas of the body and lymph node examination can help pinpoint the progression of the disease 5

1.4. World status 6

1.5. Risk factor of breast cancer 6
   - 1.5.1. Endogenous factors 6
   - 1.5.2. Environmental and lifestyle risk factors 7

1.6. Signs and symptoms of breast cancer 8

1.7. Breast cancer classification 9
   - 1.7.1. Histopathological classification 9
   - 1.7.2. Grading 10
   - 1.7.3. TNM classification 11
Contents

1.7.4. Staging

1.8. Diagnosis and detection
  1.8.1. Breast self-examination (BSE)
  1.8.2. Clinical breast exam
  1.8.3. Mammography
  1.8.4. Ultrasonography (USG)
  1.8.5. Fine needle aspiration cytology (FNAC)
  1.8.6. Core needle biopsy

1.9. Therapy
  1.9.1. Surgery
  1.9.2. Medication
    1.9.2.1. Hormone therapy
    1.9.2.2. Chemotherapy
    1.9.2.3. Targeted therapy
  1.9.3. Radiation therapy

1.10. Aims and objectives

Chapter 2

MATERIALS AND METHODOLOGIES

2.1. Materials Required
  2.1.1. Reagents for tissue processing
  2.1.2. Reagents for Immunohistochemistry
  2.1.3. Reagents required for ELISA
  2.1.4. Instruments and Other materials

2.2. Methodology
  2.2.1. Sample size and selection of patients
  2.2.2. Inclusion and Exclusion criteria
2.2.3. Collection of clinical data from patients
2.2.4. Collection of histopathological and biological data
2.2.5. Ethical Clearance
2.2.6. Sample collection
2.2.7. Tissue Processing
2.2.7.1. Fixation
2.2.7.2. Grossing
2.2.7.3. Dehydration
2.2.7.4. Embedding
2.2.7.5. Sectioning
2.2.7.6. Histopathology analysis
2.2.7.7. Immunohistochemistry
2.2.8. Serum separation
2.2.8.1. ELISA
2.2.9. Treatment and follow-up of patients

Chapter 3

EVALUATION OF BREAST CANCER RISK FACTORS

3.1. Introduction
3.1.1. Menstrual status
3.1.2. Parity
3.1.3. Lactation or breast feeding
3.1.4. Exposure to exogenous hormones (natural exposure, use of OCP and HRT)
3.1.5. Family history of breast cancer
3.1.6. BMI
### Chapter 4

**BIOLOGICAL BEHAVIOR OF BREAST CANCER —**

*Observation of clinico-pathological parameters, characteristics of molecular subtypes and BRCA status in breast cancer patients*

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1. Introduction</td>
<td>60</td>
</tr>
<tr>
<td>4.1.1. Role of histopathological parameters in breast cancer</td>
<td>60</td>
</tr>
<tr>
<td>4.1.2. Importance of the breast cancer classification into molecular subtypes</td>
<td>62</td>
</tr>
<tr>
<td>4.1.3. Breast cancer genes BRCA1 and BRCA2</td>
<td>63</td>
</tr>
<tr>
<td>4.2. Results and Discussion</td>
<td>65</td>
</tr>
<tr>
<td>4.2.1. Characteristics and frequency of East Indian breast cancer based on histopathological parameter</td>
<td>65</td>
</tr>
<tr>
<td>4.2.2. Comparison of clinicopathological characteristics among luminal A, luminal B, HER2 enriched and triple negative subtypes</td>
<td>67</td>
</tr>
<tr>
<td>4.2.3. Epidemiology of luminal cancer</td>
<td>75</td>
</tr>
<tr>
<td>4.2.4. Pattern of metastases in luminal and non-luminal cancer</td>
<td>79</td>
</tr>
<tr>
<td>4.2.5. Breast cancer gene BRCA1 and BRCA2 and their expression status in protein level among patients</td>
<td>83</td>
</tr>
<tr>
<td>4.2.6. Clinical and pathologic characteristics of breast cancer patients in relation with BRCA1 and BRCA2 expression</td>
<td>85</td>
</tr>
<tr>
<td>4.3. Conclusion</td>
<td>93</td>
</tr>
</tbody>
</table>

### Chapter 5

**SERIAL MEASUREMENT OF POST OPERATIVE CA15.3 - PREDICTIVE OF**
### Introduction

5.1.1. Chemistry of CA 15.3

5.1.2. Physiological and pathophysiological role of CA 15.3 gene (MUC1)

5.1.3. MUC1 inhibits drugs

5.1.4. Prevention of cell death by MUC1

5.1.5. MUC1 promotes tumor invasion

5.1.6. Transformation of MUC1 in malignant tumor tissue

5.1.7. Clinical utility of CA15.3

5.1.8. Advantages over traditional markers

5.1.9. Role of MUC1 in signalling pathway

5.1.9.1. MUC1 affects c-Src signalling in PyVMT-induced mammary tumorigenesis

5.1.9.2. MUC1 oncoprotein activates the IκB kinase β complex and constitutive of NF-κB signalling

5.1.10. CA 15.3 detection techniques

5.1.10.1. ELISA

5.1.10.2. ALYGNSA

5.1.11. Importance in breast cancer

5.1.12. Hypothesis

### Results & Discussion

5.2.1. CA 15.3 can be used as diagnostic tool in breast cancer

5.2.2. Correlation between pre-operative CA 15.3 and patients’ clinical and pathological parameters

5.2.3. Pre-operative CA15.3 values in different molecular subtypes

5.2.4. Pre-operative CA 15.3 levels in different histo-pathological types of breast cancer and benign diseases of breast
5.2.5. Usefulness of serum CA 15.3 as prognostic index ................................................................. 116
5.2.6. Comparison between pre-operative and post-operative CA 15.3 levels .................. 117
5.2.7. Post operative drop of CA 15.3 levels in different molecular subtypes ...................... 119
5.2.8. Clinico-pathological variables of 31 patients with PO raised CA 15.3 ......................... 121
5.2.9. Relationship between CA 15.3 levels and recurrence of breast cancer ................. 122
5.2.10. Post operative CA 15.3 status and incidence of disease recurrence ..................... 125

5.3. Conclusion ............................................................................................................................. 127

Concluding remarks .................................................................................................................. 128-130
Bibliography ............................................................................................................................... 131-145
Publications ............................................................................................................................... 146-148
Reprints .......................................................................................................................................